Combined injectable contraceptive
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Combined Injectable Contraceptive
| |
| Background | |
| B.C. type | Hormonal |
| First use | about 1980 |
| Failure rates (first year) | |
| Perfect use | 0-0.2[1]% |
| Typical use | ? |
| Usage | |
| Duration effect | 1 month |
| User reminders | ? |
| Advantages and Disadvantages | |
| STD protection | No |
| Benefits | Especially good if poor pill compliance. |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle.
History
- October 5, 2000, Pharmacia received FDA approval for Lunelle™ Monthly Contraceptive Injection.[1]
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-provera).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]
Side-effects
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]
Formulations
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.[1]
- Cyclofem contains depomedroxy-progesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
See also
Footnotes
Birth control | |
|---|---|
| Comparison: | Comparison of birth control methods |
| Behavioral: | Avoiding vaginal intercourse: Anal sex, Oral sex, Non-penetrative sex, Masturbation, Abstinence Including vaginal intercourse: Fertility awareness, Rhythm Method, Withdrawal, Breastfeeding infertility |
| Barrier: | Condom, Female condom, Diaphragm, Cervical cap, Lea's Shield |
| Spermicide: | Contraceptive sponge |
| Hormonal: | Combined: Combined oral contraceptive pill ('the Pill'), Contraceptive patch, NuvaRing, Combined injectable contraceptive Progestogen only: Progestogen only pill ('minipill'), Depo-Provera, Norplant/Jadelle, Implanon |
| Anti-estrogen: | Ormeloxifene (a.k.a. Centchroman) |
| Intra-uterine: | IUD (copper or progestogen), IUS (progestogen) |
| Post-intercourse: | Contraception: Emergency contraception (pills or copper IUD) Abortion: Surgical abortion, Medical abortion (RU-486/abortion pill) |
| Sterilization: | Male: Vasectomy Female: Tubal ligation, Essure |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
